Search | Clinical Trials Finder

Conditions: Tendonitis, Bursitis
Interventions: Ketoprofen Topical Patch 20%, Placebo; Drug · Other
Lead sponsor: APR Applied Pharma Research s.a.; Other
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Celiac Disease
Interventions: TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar; Drug · Dietary Supplement
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more

Conditions: Osteoarthritis
Interventions: Acupuncture; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Schizophrenia
Interventions: OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 17
States / cities: Little Rock, Arkansas • Garden Grove, California • Glendale, California + 12 more

Conditions: Carcinoma, Renal Cell
Interventions: Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Alcohol Use Disorder, Alcohol Drinking, Alcohol Abuse, Alcohol Dependence
Interventions: Contingency Management, Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT); Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Crohn's Disease
Interventions: CC-5013; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Tucson, Arizona • Anaheim, California • Washington D.C., District of Columbia + 2 more

Conditions: Metastatic, Uveal Melanoma
Interventions: 75mg selumetinib, placebo, Dacarbazine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Gram-negative Bacterial Infections
Interventions: ATM-AVI, BAT; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 9 Months to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: San Diego, California • New York, New York

Conditions: Palmoplantar Keratoderma
Interventions: Tapinarof; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atopic Dermatitis
Interventions: Combination of pimecrolimus and fluticasone, pimecrolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Houston, Texas

Conditions: Colitis, Ulcerative
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 56
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more

Conditions: Bone Metastases
Interventions: ExAblate 2100; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 5
States / cities: Duarte, California • San Francisco, California • Stanford, California + 2 more

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 13 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: Lennox Gastaut Syndrome
Interventions: ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 35 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Parkinson's Disease, Dyskinesia
Interventions: Sarizotan, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 30 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 32
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more

Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Hypertension Complicated
Interventions: RBPM, MII; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Boston, Massachusetts • Quincy, Massachusetts • Roslindale, Massachusetts

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions: quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy; Drug · Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Suicide
Interventions: Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement (THRIVE), Center Care as Usual; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Huntsville, Alabama • Phoenix, Arizona • Nashville, Tennessee

Conditions: Major Depressive Disorder
Interventions: AZD6765 iv, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Chino, California • Lond Beach, California • San Diego, California + 30 more

Conditions: Hypochondroplasia
Interventions: Vosoritide; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 10
States / cities: Phoenix, Arizona • Oakland, California • Wilmington, Delaware + 7 more

Search by objective public record fields.

Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Efficacy of Acupuncture With Physical Therapy for Knee Osteo-Arthritis

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Virtual Incentive Treatment for Alcohol

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

Combination Therapy for Atopic Dermatitis

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

Quetiapine for the Reduction of Cocaine Use

THRIVE: A Recovery-Focused Suicide Prevention Intervention in Crisis Stabilization Centers

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia